These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28105863)

  • 1. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.
    González-Larriba JL; Maroto P; Durán I; Lambea J; Flores L; Castellano D;
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):217-226. PubMed ID: 28105863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.
    Porta C; Giglione P; Paglino C
    Expert Opin Pharmacother; 2016; 17(5):643-55. PubMed ID: 26630127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development of mTor inhibitors for renal cancer.
    Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
    Calvo E; Ravaud A; Bellmunt J
    Cancer Treat Rev; 2013 Jun; 39(4):366-74. PubMed ID: 22832091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
    Roviello G; Generali D
    Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
    [No Abstract]   [Full Text] [Related]  

  • 7. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B; Fu S; Meng J; Lister J; Karcher H
    PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
    Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
    Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B
    Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
    Zahoor H; Rini BI
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
    Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of metastatic renal cell carcinoma: evolving new therapies.
    Kumar R; Kapoor A
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):231-237. PubMed ID: 28590313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.
    Goebell PJ; Doehn C; Grüllich C; Grünwald V; Steiner T; Ehneß R; Welslau M
    Future Oncol; 2017 Jul; 13(17):1463-1471. PubMed ID: 28523933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK; Gandhi S; George S
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
    Patel SB; Stenehjem DD; Gill DM; Tantravahi SK; Agarwal AM; Hsu J; Vuong W; Pal SK; Agarwal N
    Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
    Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
    Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.